RB1 and myeloid leukemia: In addition to PCa cells, suppression of NF-κB activation by RB was observed in other different cancer cell lines, including myeloid leukemia cells (K562, AO2), and liver hepatocellular cells (HepG2), indicating that inactivation of NF-κB by RB is a general mechanism for its antitumor activity.